Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.9 USD | +2.30% |
|
-0.38% | -18.65% |
06-14 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating | MT |
06-14 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.65% | 3.44B | |
+15.03% | 122B | |
+19.54% | 113B | |
+8.24% | 22.84B | |
-20.29% | 20.72B | |
-16.19% | 16.51B | |
-12.91% | 16.39B | |
-44.35% | 15.83B | |
+1.58% | 13.49B | |
+65.45% | 11.67B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 09